Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
6.35
Dollar change
-0.76
Percentage change
-10.69
%
IndexRUT P/E- EPS (ttm)-2.13 Insider Own57.85% Shs Outstand97.38M Perf Week-17.32%
Market Cap762.19M Forward P/E- EPS next Y-1.51 Insider Trans16.04% Shs Float50.59M Perf Month-9.80%
Income-204.50M PEG- EPS next Q-0.39 Inst Own34.66% Short Float22.64% Perf Quarter-9.54%
Sales0.59M P/S1291.85 EPS this Y25.01% Inst Trans- Short Ratio13.81 Perf Half Y-31.50%
Book/sh2.03 P/B3.13 EPS next Y7.56% ROA-65.09% Short Interest11.45M Perf Year-57.69%
Cash/sh1.76 P/C3.62 EPS next 5Y- ROE-78.27% 52W Range4.11 - 15.75 Perf YTD-28.33%
Dividend Est.- P/FCF- EPS past 5Y-193.88% ROI-72.82% 52W High-59.68% Beta2.39
Dividend TTM- Quick Ratio8.91 Sales past 5Y-25.00% Gross Margin-1850.08% 52W Low54.50% ATR (14)0.58
Dividend Ex-DateSep 10, 2019 Current Ratio8.91 EPS Y/Y TTM-33.33% Oper. Margin-33773.27% RSI (14)45.38 Volatility8.38% 8.24%
Employees234 Debt/Eq0.18 Sales Y/Y TTM- Profit Margin-34601.86% Recom1.33 Target Price14.18
Option/ShortYes / Yes LT Debt/Eq0.15 EPS Q/Q0.97% Payout- Rel Volume0.95 Prev Close7.11
Sales Surprise-69.25% EPS Surprise3.28% Sales Q/Q- EarningsMay 10 BMO Avg Volume829.57K Price6.35
SMA20-9.80% SMA504.17% SMA200-17.25% Trades Volume787,425 Change-10.69%
Date Action Analyst Rating Change Price Target Change
May-20-24Initiated H.C. Wainwright Buy $10
May-16-24Upgrade Citigroup Neutral → Buy $10
Apr-22-24Initiated Chardan Capital Markets Buy $17
Apr-08-24Initiated TD Cowen Buy
Apr-03-24Initiated Wedbush Outperform $12
Jan-16-24Downgrade Stifel Buy → Hold $18 → $9
Dec-08-23Initiated Citigroup Neutral $10
Oct-09-23Initiated BMO Capital Markets Outperform $19
Jul-31-23Initiated Guggenheim Buy $24
Apr-18-23Initiated Stifel Buy $18
May-30-24 09:55AM
08:00AM
May-29-24 06:30AM
May-25-24 04:10AM
May-20-24 09:32PM
09:33AM Loading…
09:33AM
May-17-24 06:27AM
06:15AM
May-16-24 07:14AM
May-14-24 09:55AM
May-13-24 11:12AM
08:00AM
May-12-24 03:00AM
May-10-24 02:23PM
01:53PM
08:00AM Loading…
08:00AM
May-08-24 08:00AM
May-03-24 12:00PM
May-01-24 08:00AM
Apr-30-24 06:01AM
Apr-29-24 10:12AM
07:35AM
07:33AM
07:00AM
Apr-23-24 08:00AM
Mar-27-24 08:45AM
Mar-14-24 02:44PM
Mar-01-24 02:00PM
08:00AM
Feb-29-24 03:02AM
08:00AM Loading…
Feb-28-24 08:00AM
Feb-20-24 04:01PM
Feb-14-24 11:50PM
04:05PM
Feb-01-24 08:00AM
Jan-25-24 08:00AM
Jan-09-24 06:21PM
Jan-05-24 05:00PM
08:00AM
Jan-02-24 08:00AM
Dec-19-23 10:30AM
Nov-30-23 07:45AM
Nov-08-23 08:00AM
Nov-03-23 04:01PM
Oct-30-23 03:46PM
Oct-27-23 06:00AM
Oct-24-23 07:30AM
05:04AM
Oct-23-23 02:50AM
Oct-17-23 08:00AM
Oct-09-23 09:33AM
Sep-19-23 08:00AM
Aug-31-23 08:00AM
Aug-07-23 04:01PM
Jul-25-23 07:45AM
Jun-29-23 08:46AM
Jun-22-23 08:00AM
Jun-02-23 10:15AM
May-31-23 08:00AM
May-26-23 09:45AM
May-17-23 04:05PM
06:00AM
May-11-23 08:00AM
Mar-27-23 08:00AM
Mar-09-23 08:00AM
Feb-27-23 08:00AM
Jan-20-23 05:56AM
Jan-09-23 07:00AM
Jan-03-23 08:00AM
Nov-01-22 04:13PM
Oct-24-22 05:30PM
Oct-20-22 12:45PM
Oct-19-22 09:47PM
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARCH Venture Partners XII, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:38 PM
ARCH Venture Partners X, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:37 PM
NELSEN ROBERTDirectorFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 05:41 PM
GV 2019 GP, L.L.C.10% OwnerJun 21 '23Sale14.9719,003284,4960Jun 22 05:03 PM
GV 2019 GP, L.L.C.10% OwnerJun 20 '23Sale15.0637,405563,2480Jun 22 05:03 PM